by MM360 Staff | Nov 15, 2025 | Publications
Leuk Lymphoma. 2025 Oct;66(10):1767-1777. doi: 10.1080/10428194.2025.2513676. Epub 2025 Jun 3. ABSTRACT Eligibility for autologous transplantation is a key factor for tailoring treatment decisions in patients with newly-diagnosed multiple myeloma. For non-eligible...
by MM360 Staff | Nov 10, 2025 | Publications
J Natl Cancer Inst. 2025 Nov 9:djaf326. doi: 10.1093/jnci/djaf326. Online ahead of print. ABSTRACT INTRODUCTION: Although myeloma represents a key success story in oncology, some drugs have failed to meet primary endpoints in randomized controlled trials (RCTs),...
by MM360 Staff | Nov 2, 2025 | Publications
Chin Med J (Engl). 2025 Oct 31. doi: 10.1097/CM9.0000000000003832. Online ahead of print. NO ABSTRACT PMID:41173804 | DOI:10.1097/CM9.0000000000003832
by MM360 Staff | Oct 25, 2025 | Publications
Ann Hematol. 2025 Sep;104(9):4791-4809. doi: 10.1007/s00277-025-06524-6. Epub 2025 Sep 9. ABSTRACT Despite therapeutic advances, multiple myeloma (MM) remains incurable, especially in relapsed/refractory (R/R) cases. B-cell maturation antigen (BCMA) is a key target...
by MM360 Staff | Oct 18, 2025 | Publications
Spine J. 2025 Oct 14:S1529-9430(25)00850-2. doi: 10.1016/j.spinee.2025.10.018. Online ahead of print. ABSTRACT BACKGROUND CONTEXT: Bone disease in patients with multiple myeloma (MM) is associated with vertebral complications, which include vertebral fractures and...
by MM360 Staff | Oct 14, 2025 | Publications
Clin Hematol Int. 2025 Oct 8;7(4):1-20. doi: 10.46989/001c.144582. eCollection 2025. ABSTRACT Multiple myeloma (MM) treatment outcomes in developing countries may be impacted by resource constraints. This systematic review and meta-analysis evaluated efficacy outcomes...